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Background: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease of unknown causes. Three proteins (mammalian
target of rapamycin, mTOR; zinc finger E-box-binding homeobox 1, ZEB1; Rho-associated, coiled-coil containing protein
kinase 1, ROCK1) may be related to pulmonary fibrosis. However, they have not been assessed in human pulmonary
fibrosis. We assessed the clinical significance of mTOR, ZEB1, and ROCK1 expression in human pulmonary fibrosis
of usual interstitial pneumonia (UIP) pattern.
Methods: The mTOR, ZEB1, and ROCK1 expression was evaluated by immunohistochemical staining of 30 surgical lung
biopsy tissues from 26 IPF and 4 UIP pattern connective tissue disease related interstitial lung disease (CTD-ILD) patients.
The expression scores correlated with the clinical features.
Results: The mTOR, ZEB1 and ROCK1 mainly expressed in alveolar epithelial cells of UIP lungs. The histological fibrosis
scores and lung function decline in the strong mTOR expression group were higher than those in the weak and
intermediate expression group. Patients with positive ZEB1 expression had higher fibrosis scores and greater decline in
carbon monoxide diffusion capacity (DLCO) than patients with negative ZEB1 expression. Patients with positive mTOR
or ZEB1 expression had poorer prognosis than that of patients with negative mTOR or ZEB1 expression, although it was
not statistically significant. ROCK1 was not associated with the studied clinicopathological features.
Conclusions: The mTOR and ZEB1 expression in pulmonary fibrosis patients significantly correlated with the fibrosis
score and lung function decline, indicating that it may be related to the prognosis of pulmonary fibrosis. Further studies
involving large numbers of homogeneous IPF patients are warranted.
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Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, irreversible, lethal lung disease of unknown cause,
histologically defined as usual interstitial pneumonia (UIP)
[1]. The initiating injury and subsequent pathways for IPF
have not been elucidated, but the disease is considered to
be an epithelial fibrotic disorder. It is characterized by epi-
thelial injury followed by aberrant wound healing with
excessive fibrosis and minimal inflammation. In these* Correspondence: ywkim@snu.ac.kr
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unless otherwise stated.processes, growth factors, cytokines, and other mediators
are released, followed by excessive extracellular matrix de-
posit and abnormal mesenchymal cell proliferation in the
lungs. However, little is known about the detailed patho-
genesis of pulmonary fibrosis development.
Mammalian target of rapamycin (mTOR) complex is a
highly conserved intracellular serine/threonine kinase and a
major downstream component of phosphatidyl inositol 3-
kinase (PI3K). The mTOR regulate translation of specific
mRNAs and protein synthesis involved in cell cycle regula-
tion and has been shown to influence tissue fibrosis [2]. A
previous study demonstrated that the initiation and pro-
gression of pulmonary fibrosis was prevented by the admin-
istration of rapamycin, an mTOR inhibitor, to a transgenic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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expression of the EGFR ligand, transforming growth
factor (TGF)-α [3]. In addition, a previously published
case study reported that rapamycin was successfully used
to treat a patient with IPF [4].
Zinc finger E-box-binding homeobox 1 (ZEB1) protein is
a key transcription factor that acts downstream of TGF-β
which has been implicated in the epithelial-mesenchymal
transition (EMT) [5]. The EMT is thought to contribute to
development of pulmonary fibrosis. Furthermore, there is a
report that ZEB1 gene is overexpressed in the lung tissues
of interstitial lung disease patients [6].
Rho-associated, coiled-coil containing protein kinase 1
(ROCK1) is a serine/threonine kinase and a downstreamFigure 1 Representative lung tissue sections of usual interstitial pneu
and expression levels observed with the different markers. Low-powe
hematoxylin and eosin staining, 40× magnification) The mTOR and ZEB1 expr
from fibrotic areas (C, mTOR intermediate; D, mTOR strong; E, ZEB1 intermedi
cells, mesenchymal cells, macrophages and lymphocytes of the UIP patients (
staining, brown color, 400× magnification.effector of Rho. It controls cell adhesion and cell motility
via actin-cytoskeleton reorganization and actin-myosin fila-
ment bundles regulation. A previous study demonstrated
that RhoA/ROCK inhibitor attenuated pulmonary fibrosis
in animal models [7].
Therefore, it is hypothesized that mTOR pathway, ZEB1,
and ROCK1 may play a role in the pathogenesis of pul-
monary fibrosis. However, these proteins have not been
assessed in human pulmonary fibrosis. This study was
performed to identify the clinical significance of mTOR,
ZEB1, and ROCK1 expression in the lung tissues of idio-
pathic pulmonary fibrosis and UIP pattern connective
tissue disease related interstitial lung disease (CTD-ILD)
patients.monia patients exemplifying the two principal grades of fibrosis
r images showing grade of fibrosis (A, grade 1 fibrosis; B, grade 7 fibrosis;
essed in hyperplastic alveolar epithelial cells and some mesenchymal cells
ate; F, ZEB1 strong). ROCK1 expressed in hyperplastic alveolar epithelial
G, ROCK1 intermediate; H, ROCK1 strong). (C-H); immunohistochemical
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Study population
We enrolled 30 pulmonary fibrosis patients from January
2005 to May 2010 at Seoul National University Hospital.
The study included patients who underwent surgical lung
biopsy, and were histologically diagnosed with usual inter-
stitial pneumonia (UIP). The pathological diagnosis was
undertaken using previously established criteria, and clin-
ical diagnosis was judged according to the international
guidelines [8]. Two normal lung tissues were obtained from
certified tissue bank to compare with UIP lungs. TheTable 1 Characterstics of the study patients
Variables N = 30
Age, years, median (range) 57 (38-74)
Male sex 14 (46.7)
Smoking
Never smoker 19 (63.3)
Former smoker 7 (23.3)
Current smoker 4 (13.3)
Follow up, months 40 (5-74)
Connective tissue disease 4 (13.3)
Arterial blood gas analysis (n = 28)
pH 7.41 ± 0.0
PaO2, mmHg 92.0 ± 16.0
PaCO2, mmHg 40.2 ± 4.0
Saturation, % 96.7 ± 1.7
White blood cell count
Neutrophil, /mm3 4003 ± 1271
Lymphocyte, /mm3 2327 ± 876
Bronchoalveolar lavage (n = 15)
Alveolar macrophage, % 46.1 ± 21.1
Neutrophil, % 23.0 ± 22.2
Lymphocyte, % 17.5 ± 9.9
Pulmonary function test
FVC, % 75.3 ± 12.9
FEV1, % 86.9 ± 13.5
DLCO, % 65.0 ± 25.2
Radiologic features
Ground glass opacities 20 (66.7)
Reticular density 10 (33.3)
Consolidation 3 (10.0)
Traction bronchiectasis 1 (3.3)
Honeycombing 11 (36.7)
Steroids or immunosuppressive treatment 16 (53.3)
Survivors 24 (80.0)
Definition of abbreviations: FVC = forced vital capacity, FEV1 = forced expiratory
volume in 1 s, DLCO = carbon monoxide diffusion capacity.
Data are presented as mean ± SD or numbers (%).demographic characteristics, pulmonary function, and
chest computed tomography (CT) scan images of the
study patients were reviewed. The survival data of the
patients were obtained from the Ministry of Public Ad-
ministration and Security. A part of the patient data was
reported in a previous study [9]. This study was approved
by the Institutional Review Board of the Seoul National
University Hospital (H-1105-099-363).
Immunohistochemical staining
The expression of mTOR, ZEB1, and ROCK1 was evalu-
ated by immunohistochemical staining of formalin-fixed
and paraffin-embedded lung tissue sections, which were
cut to a thickness of 4 μm. After deparaffinization in xylene
and rehydration using graded alcohol to water, these
slides were soaked in Target Retrieval Solution (Dako,
Carpenteria, CA, USA), and then placed in a water bath
at 97°C for 20 min to enable antigen retrieval. The sec-
tions were then immersed for 5 min in distilled water
containing 3% hydrogen peroxidase to block endogenous
peroxidase activity. The sections were incubated for 30 min
with primary antibodies for mTOR, ZEB1, and ROCK1 di-
luted 1:200, 1:100 and 1:50, respectively. The primary rabbit
monoclonal mTOR and ROCK1 antibodies were purchased
from Abcam (Cambridge, MA, USA). The primary goat
polyclonal ZEB1 antibody was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The Dako EnVision+Table 2 Comparisons of clinical characteristics between
idiopathic pulmonary fibrosis and connective tissue
disease related interstitial lung disease of histologic
usual interstitial pneumonia pattern
IPF CTD-ILD p value
(n = 26) (n = 4)
Age, years, median (range) 62 (38-74) 52 (48-55) 0.139
Male sex 14 (53.8) 0 0.066
Ever smoker 11 (42.3) 0 0.141
Pulmonary function test
FVC, % 73.4 ± 15.6 78.0 ± 15.9 0.746
FEV1, % 85.4 ± 16.3 85.0 ± 17.9 0.837
DLCO, % 62.8 ± 28.8 65.7 ± 22.2 0.825
Histologic fibrosis score 12.9 ± 8.0 8.6 ± 12.9 0.220
Radiologic honeycombing score 2.1 ± 1.9 1.5 ± 1.9 0.791
mTOR expression score 4.4 ± 2.8 2.7 ± 4.2 0.245
ZEB1 expression score 3.2 ± 2.6 2.5 ± 3.0 0.576
ROCK1 expression score 3.4 ± 2.9 1.7 ± 1.7 0.359
Steroids or immunosuppressive
treatment
12 (46.2) 4 (100) 0.089
Definition of abbreviations: IPF = idiopathic pulmonary fibrosis, CTD-ILD =
connective tissue disease related interstitial lung disease, FVC = forced vital
capacity, FEV1 = forced expiratory volume in 1 s, DLCO = carbon monoxide
diffusion capacity.
Data are presented as mean ± SD or numbers (%).
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polymer was used along with LSAB®2 (Dako, Carpenteria,
CA, USA), a streptavidin-peroxidase conjugate that serves
as the secondary antibody. Routinely processed tissue sec-
tions of prostate cancer, breast cancer, and thyroid cancer
were used as positive staining controls for mTOR, ZEB1,
and ROCK1 staining, respectively. Staining without the
primary antibody was also performed to verify staining
specificity.Histologic analysis
Two pathologists reviewed the histology slides independ-
ently and without access to the clinical data. The fibrosis
score was analyzed using the hematoxylin-and-eosin-
stained lung section slides. The extent of fibrotic lesions was
scored as 0 (0-10%), 1 (10-25%), 2 (25-50%), 3 (50-75%), or
4 (75-100%). The severity of fibrosis was scored from 0
(normal lung) to 8 (total fibrosis) by determining the
average of 10 distinct microscopic fields at 200× magni-
fication in accordance with the Ashcroft scoring system
(Figure 1A,B) [10]. Finally, fibrosis scores were calculated
by multiplication of the extent of fibrotic lesions to Ash-
croft scores. The expression of mTOR, ZEB1, and ROCK1
was scored using both the intensity of staining and the
percentage of positively stained alveolar epithelial cells.
The total expression score was calculated by multiplyingFigure 2 Representative lung tissue sections from healthy individuals
mTOR, ZEB1, and ROCK1. The mTOR, ZEB1 and ROCK1 expression was n
(Figure 2A, E, I, immunohistochemical staining, brown color, 200× magnif
(Figure 2B, F, J, 400× magnification). Cells overlying fibroblastic foci show
did not show mTOR, ZEB1 and ROCK1 expression (Figure 2C, G, K; arrows
of mTOR, ZEB1 and ROCK1 was compared in same fibrotic area (Figure 2Dintensity score (0, negative; 1, weak; 2, moderate; 3, strong)
to the score of the positively stained cells (0, <10%; 1, 10–
49%; 2, 50–75%; 3, >75%). We randomly selected 10 micro-
scopic fields under 100× magnification. Each field was
individually assessed and the expression score was de-
termined by obtaining the mean score of all the fields.
Finally, the expression level was graded as negative (0),
intermediate (1–3), or strong (≥4) based on the total
expression score (Figure 1C-H).Radiological analysis
Honeycombing on the chest CT scan images was defined
as air-filled cysts with thick-walled, between the sizes of
several millimeters to several centimeters in diameter. A
previously published method [11] was used to assess the
honeycombing score. Briefly, the whole lung was divided
into 6 lobes (right upper, right middle, right lower, left
upper, lingular division, and left lower lobe), and the extent
of the honeycombing lesion was assessed as 0 (absent), 1
(0–25%), 2 (25–50%), 3 (50–75%), or 4 (<75%) in each
lobe. The honeycombing score was the final sum of all
6 lobes.Statistical analysis
The differences in patients’ characteristics, on the basis
of the expression of mTOR, ZEB1, and ROCK1, wereand patients with usual interstitial pneumonia (UIP), stained for
ot detected in alveolar epithelial cells of control normal lung tissue
ication). Staining was weak or absent in normal area of UIP lungs
ed weak staining, however mesenchymal cells of the fibroblastic foci
denote location of fibroblastic focus, 400× magnification). Expression
, H, L, 400× magnification).
Table 3 Clinical characteristics according to the
expression of mTOR
mTOR negative,






64 (38-74) 57 (38-70) 0.714
Male sex 5 (38.5) 9 (52.9) 0.484
Ever smoker 4 (30.8) 7 (41.2) 0.708
FVC, % 73.0 ± 15.2 74.8 ± 16.1 0.748
DLCO, % 62.1 ± 20.3 64.1 ± 32.7 0.857
PaO2, mmHg 99.8 ± 18.1 86.2 ± 11.6 0.023
BAL Neutrophil, % 25.5 ± 24.5 21.3 ± 21.9 0.736
BAL Lymphocyte, % 22.5 ± 12.9 14.2 ± 6.0 0.116
Radiologic
honeycombing score
1.7 ± 2.7 2.4 ± 2.6 0.351
Histologic fibrosis
score
10.1 ± 8.7 15.0 ± 8.1 0.034
Δ FVC, mL 109 ± 375 -151 ± 174 0.044
Δ DLCO, mL/mmHg/
min
0.72 ± 2.24 -1.19 ± 1.36 0.023
Δ FVC, % 6.7 ± 17.1 - 4.4 ± 4.9 0.041
Δ DLCO, % 5.2 ± 12.9 - 5.2 ± 6.2 0.021
Survivors 11 (84.6) 13 (76.5) 0.672
ZEB1 2.4 ± 2.4 3.7 ± 2.8 0.185
ROCK1 1.6 ± 1.9 4.4 ± 2.9 0.006
Definitions of abbreviations: BAL = bronchoalveolar lavage.
Δ: change of pulmonary function per year (final minus initial
pulmonary function).
Data are presented as mean ± SD or numbers (%) and analyzed by the Fisher’s
exact test or Mann-Whitney test.
Park et al. BMC Pulmonary Medicine 2014, 14:168 Page 5 of 9
http://www.biomedcentral.com/1471-2466/14/168analyzed by using the Mann-Whitney Test for continuous
variables and Fisher’s exact test for categorical variables
using SPSS 18.0 statistical software. Pearson’s test was used
to verify the association between fibrosis score and mTOR,
ZEB1, and ROCK1 expression. A Kaplan-Meier curve was
plotted for survival analysis. A p-value of <0.05 was consid-
ered as significant.
Results
Characteristics of the study patients
The median age of the patients was 57 years (range, 38–74
years), including 14 male patients (46.7%; Table 1). Four
patients had connective tissue disease (CTD), however
histologic patterns were UIP. Sixteen patients were on ster-
oid or immunosuppressive treatment. The mean forced
vital capacity (FVC) and carbon monoxide diffusion cap-
acity (DLCO) of the patients was 75% and 65%, respectively.
The patient survival rate during the follow-up period
(median, 40 months; range, 5–74 months) was 80%
(24 patients survived). Baseline clinical characteristics
were not different between the patients with IPF and
CTD-ILD (Table 2).
Expression of mTOR, ZEB1 and ROCK1 in the lung tissues
of pulmonary fibrosis
The mTOR and ZEB1 were mainly expressed in the hyper-
plastic alveolar epithelial cells and in some mesenchymal
cells of UIP lungs (Figure 1C,D,E,F). The ROCK1 expres-
sion was detected in the hyperplastic alveolar epithelial
cells, some mesenchymal cells, macrophages, and lympho-
cytes of the UIP patients (Figure 1G,H). The mTOR, ZEB1
expression was not detected in the control normal lung tis-
sue, except in the bronchial epithelial cells (Figure 2A, E).
ROCK1 expression was not detected in the normal lung tis-
sue alveolar epithelial cells, but detected in bronchial epithe-
lial cells and surrounding smooth muscle cells (Figure 2I).
Cells overlying fibroblastic foci showed weak staining,
however mesenchymal cells of the fibroblastic foci did not
show mTOR, ZEB1 and ROCK1 expression (Figure 2C, G, K).
Staining was weak or absent in normal area of UIP lungs
(Figure 2B, F, J).
The correlation of the 3 markers with each other was
evaluated (Tables 3, 4 and 5). The mTOR strong expres-
sion group showed higher ROCK1 expression scores
(p = 0.006); however, ZEB1 expression scores were not
related to the mTOR scores (Table 3).
Clinical characteristics in relation to the expression of mTOR
The strong mTOR expression group had significantly
higher (p = 0.034) histological fibrosis scores than those
of the negative and intermediate expression groups
(Table 3). In addition, the annual decline in FVC and DLCO
was higher in the strong mTOR expression group than that
in the negative and intermediate expression groups (Table 2).PaO2 was lower in strong expression group than in the
negative and intermediate expression groups (p = 0.023).
The strong mTOR expression group had significantly
higher ROCK1 expression scores than those of the nega-
tive and intermediate expression groups. The mTOR ex-
pression score significantly correlated with the fibrosis
score (r = 0.441, p = 0.015; Figure 3A). However, mTOR
expression did not correlate with the honeycombing score,
FVC, and DLCO. During the study period, no fatality was
observed in the mTOR-negative group. In contrast, the
mTOR-positive (intermediate and strong) group had 6 fa-
talities. (Figure 4A; p = 0.325).Clinical characteristics in relation to ZEB1 expression
Patients with positive (intermediate and strong) ZEB1
expression showed higher fibrosis scores, greater annual
rate of decline in DLCO (% predicted), and higher mTOR
scores than that of patients with negative ZEB1 expres-
sion (Table 4). The ZEB1 expression score did not sig-
nificantly correlate with the fibrosis score (Figure 3B),
honeycombing score, FVC, and DLCO. Similar to the find-
ings related to mTOR lung tissue expression, no fatality
Table 5 Clinical characteristics according to the
expression of ROCK1
ROCK1 negative,






63 (39-74) 55 (38-72) 0.110
Male sex 7 (43.8) 7 (50.0) 1.000
Ever smoker 6 (37.5) 5 (35.7) 1.000
FVC, % 73.6 ± 13.6 74.5 ± 17.9 0.871
DLCO, % 58.4 ± 21.7 68.8 ± 33.2 0.332
PaO2, mmHg 92.8 ± 12.3 91.1 ± 19.9 0.784
BAL Neutrophil, % 32.4 ± 26.8 14.7 ± 14.3 0.129
BAL Lymphocyte, % 18.8 ± 12.5 16.3 ± 7.6 0.646
Radiologic
honeycombing score
1.7 ± 2.7 2.4 ± 2.6 0.496
Histologic fibrosis
score
10.1 ± 8.7 15.0 ± 8.1 0.123
Δ FVC, mL - 20 ± 190 - 45 ± 401 0.856
Δ DLCO, mL/mmHg/
min
- 0.05 ± 1.72 - 0.59 ± 2.33 0.547
Δ FVC, % 0.4 ± 6.3 0.8 ± 17.8 0.936
Δ DLCO, % 1.0 ± 10.3 -1.9 ± 11.9 0.530
Survivors 12 (75.0) 12 (85.7) 0.657
mTOR 3.1 ± 2.9 5.4 ± 2.7 0.033
ZEB1 2.9 ± 2.9 3.4 ± 2.3 0.361
Definitions of abbreviations: BAL = bronchoalveolar lavage.
Δ: change of pulmonary function per year (final minus initial
pulmonary function).
Data are presented as mean ± SD or numbers (%) and analyzed by the Fisher’s
exact test or Mann-Whitney test.









61 (52-74) 57 (38-72) 0.362
Male sex 1 (25.0) 13 (50.0) 0.602
Ever smoker 2 (50.0) 9 (34.6) 0.611
FVC, % 86.0 ± 17.5 72.2 ± 14.7 0.099
DLCO, % 61.5 ± 19.7 63.5 ± 29.1 0.892
PaO2, mmHg 88.1 ± 5.5 92.7 ± 17.1 0.606
BAL Neutrophil, % 37.6 ± 31.6 19.3 ± 19.3 0.213
BAL Lymphocyte, % 13.3 ± 5.6 18.5 ± 10.6 0.433
Radiologic
honeycombing score
1.5 ± 3.0 2.1 ± 2.6 0.656
Histologic fibrosis
score
1.6 ± 1.3 14.0 ± 8.0 <0.001
Δ FVC, mL 105 ± 487 - 47 ± 298 0.517
Δ DLCO, mL/mmHg/
min
2.16 ± 3.54 - 0.57 ± 1.77 0.067
Δ FVC, % 4.8 ± 17.6 0.2 ± 13.0 0.647
Δ DLCO, % 14.0 ± 21.5 - 1.8 ± 9.1 0.047
Survivors 4 (100) 20 (76.9) 0.557
mTOR 1.5 ± 3.0 4.6 ± 2.8 0.039
ROCK1 1.3 ± 0.9 3.5 ± 2.9 0.183
Definitions of abbreviations: BAL = bronchoalveolar lavage.
Δ: change of pulmonary function per year (final minus initial
pulmonary function).
Data are presented as mean ± SD or numbers (%) and analyzed by the Fisher’s
exact test or Mann-Whitney test.
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p = 0.326).
Clinical characteristics in relation to ROCK1 expression
Pulmonary function, honeycombing, and histological fi-
brosis scores were not different among ROCK1 negative,
intermediate, and strong expression groups (Table 5).
However, ROCK1 expression was associated with fibrosis
score (r = 0.441, p = 0.024; Figure 3C). Survival was
not significantly associated with the ROCK1 expres-
sion (Figure 4C).
Discussion
This was the first study to evaluate mTOR, ZEB1, and
ROCK1 expression in the lung tissues of pulmonary fibrosis
patients. We evaluated the expression of mTOR, ZEB1, and
ROCK1 proteins in the lung tissue, along with clinical pa-
rameters such as radiological honeycombing score, histo-
logical fibrosis score, pulmonary function, and patient
survival rate. The expression of mTOR, ZEB1, and ROCK1
was increased in most of the lung tissues of pulmonary fi-
brosis patients. The expression of mTOR and ZEB1 sig-
nificantly correlated with the fibrosis score and pulmonaryfunction change. During the follow-up period, there
were no fatalities in the patient group with undetectable
mTOR or ZEB1 expression. However, ROCK1 expression
was not associated with the assessed clinicopathologic
features.
In clinical settings, mTOR inhibitors are used as im-
munosuppressants to prevent graft rejection. Activated
mTOR complex regulates cell cycle and therefore, treat-
ment with mTOR inhibitors, such as rapamycin, leads to
cell cycle arrest in the G1 phase. The key immunosuppres-
sion mechanism of mTOR inhibitors is to block clonal
proliferation and expansion of stimulated lymphocytes.
However, mTOR inhibitors also block proliferation of
other cell types such as vascular smooth muscle cells,
mesangial cells, and endothelial cells and have anti-
fibrotic activity [12]. The anti-fibrotic effects of mTOR
inhibition have been reported in various rat models of
diabetic nephropathy, glomerulosclerosis, tubulointerstitial
fibrosis, and liver cirrhosis [13-16]. In the murine pulmon-
ary fibrosis model, rapamycin treatment resulted in re-
duced lung collagen deposition [3,17,18]. However, the
role of mTOR in human pulmonary fibrosis has not been
evaluated.
Figure 3 Association of mTOR(A), ZEB1(B), and ROCK1(C) expression with fibrosis score.
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most of the UIP lung tissues and significantly correlated
with the fibrosis score and pulmonary function change.
Thus, mTOR expression may be related to the prognosis
of pulmonary fibrosis. mTOR was mainly expressed in
the alveolar epithelial cells of pulmonary fibrosis patients.
The alveolar epithelial cells have a crucial role in pathogen-
esis of IPF. Repetitive microinjuries to the alveolar epithe-
lium drive a pathogenic cascade of IPF. Activated alveolar
epithelial cells stimulate fibroblasts to secrete various profi-
brotic cytokines [19]. mTOR expression in the alveolar epi-
thelial cells indicates that mTOR may play a role in the
pathogenesis of IPF by promoting alveolar epithelial
cell proliferation. Although mesenchymal cells such as
fibroblasts or myofibroblasts rarely expressed mTOR in
our study, a previous study showed that an mTOR in-
hibitor suppressed fibroblast growth [20]. Recently, it was
reported that rapamycin suppressed TGF-β1-induced ex-
pression of collagen and fibronectin levels in primary
human lung fibroblasts [21]. The role of mTOR should be
further evaluated not only in fibroblasts but also in alveo-
lar epithelial cells.Figure 4 Patient survival in association with the expression of mTOR(
expression group and (+) represents intermediate and strong expressConsidering the antiproliferative effect of the mTOR in-
hibitors [12] and expression of mTOR in UIP lungs, mTOR
inhibitor may be a potential therapeutic drug for the treat-
ment of IPF. The effectiveness of rapamycin (sirolimus)
for IPF is currently under investigation in a pilot clinical
trial [22].
Epithelial-mesenchymal transition (EMT) induced by
TGF-β is thought to be a potential mechanism underlying
the development of pulmonary fibrosis. TGF-β induces
EMT by both Smad-dependent and Smad-independent
signaling events [23]. Smad-dependent signaling up-
regulates the expression of several transcription factors,
including Snail, Slug, Twist, and members of the ZFH
family, ZEB1 and ZEB2, all of which are essential for EMT
induction. These transcription factors activate EMT by
binding to the E-box elements present in the E-cadherin
promoter and by suppressing the synthesis of E-cadherin,
a cell-cell adhesion protein [24]. A recent study revealed
that the ZEB1 gene is overexpressed in the lung tissues
from patients with interstitial lung disease [6]. In our
study, ZEB1 was overexpressed in the alveolar epithelial
cells from pulmonary fibrosis patients. Moreover, ZEB1A), ZEB1(B) and ROCK1(C) expression; (-) represents negative
ion group.
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DLCO.
In addition to Smad pathway, multiple signaling proteins
have been implicated in the TGF-β-induced EMT. ROCK
is one of the proteins associated with EMT [25]. ROCK in-
hibitor with ZEB1/ZEB2 knockdown restored epithelial
proteins from the mesenchymal state of renal tubular epi-
thelial cells [26]. A previous study reported that treatment
with ROCK inhibitor reduced the fibrosis score in a
murine lung fibrosis model [7]. However, ROCK1 expres-
sion was not associated with any other clinicopathological
characteristics in our study.
Further studies are required to address the findings of
our data. For examples, functional studies are needed to
identify the role of mTOR, ROCK1, and ZEB1 in the
pathogenesis of pulmonary fibrosis. In addition, we in-
cluded CTD-ILD patients that showed UIP features in
lung tissue. At enrollment, these patients were diag-
nosed with IPF. However, the diagnosis was changed to
CTD-ILD on follow-up visits due to the late presenta-
tion of CTD symptoms. It is possible that the marker
expression were influenced by the inclusion of other
disease types (CTD-ILD) that were not IPF. However,
baseline lung function and expression scores of each
marker were not different in patients with IPF and
CTD-ILD. After excluding 4 patients with CTD-ILD,
change of lung function decline and fibrosis scores were
related to the mTOR and ZEB1 expression level (data
not shown).
Furthermore, a study with a large sample size is required
to evaluate whether the association of patient survival rate
with the expression level of mTOR and ZEB1 is statistically
significant.Conclusions
We first demonstrated that mTOR, ZEB1 and ROCK1 was
expressed in hyperplastic alveolar epithelial cells of human
pulmonary fibrosis lungs. Furthermore, mTOR and ZEB1
were associated with clinical outcomes such as lung
function decline. Thus, mTOR and ZEB1 expression may
be related with the prognosis of pulmonary fibrosis and
disease progression. Because our patients included some
patients with CTD-ILD, further studies involving large
numbers of homogeneous IPF patients are warranted to
determine whether mTOR and ZEB1 are true prognostic
markers of pulmonary fibrosis.Abbreviations
mTOR: mammalian target of rapamycin; ROCK1: Rho-associated, coiled-coil
containing protein kinase 1; UIP: Usual interstitial pneumonia; ZEB1: Zinc
finger E-box-binding homeobox 1.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
JSP and YWK conducted the study, drafted the manuscript. YSP and HJP
reviewed and analyzed the histology slides. SML, JJY, CGY, YWK, SKH
designed this study. All authors read and approved the final manuscript.
Acknowledgments
This study was supported by a grant of Korea Healthcare Technology R&D
Project, Ministry of Health & Welfare, Republic of Korea (A100190).
Author details
1Division of Pulmonary and Critical Care Medicine, Department of Internal
Medicine, Seoul National University College of Medicine, Seoul National
University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea. 2Department
of Pathology, Seoul National University Bundang Hospital, Seongnam-si,
Gyeonggi-do, Korea. 3Division of Pulmonary and Critical Care Medicine,
Department of Internal Medicine, Seoul National University College of
Medicine, Seoul National University Hospital, Medicine, 101 Daehak-ro,
Jongno-gu, Seoul 110-744, Korea.
Received: 20 July 2013 Accepted: 15 October 2014
Published: 31 October 2014
References
1. King TE Jr, Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet 2011,
378(9807):1949–1961.
2. Hartford CM, Ratain MJ: Rapamycin: something old, something new,
sometimes borrowed and now renewed. Clin Pharmacol Ther 2007,
82(4):381–388.
3. Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett
JA, Hardie WD: Rapamycin prevents transforming growth factor-alpha-
induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2009, 41(5):562–572.
4. Buschhausen L, Kamm M, Arns W, Schulze-Lohoff E, Weber M: [Successful
treatment of a severe case of idiopathic pulmonary fibrosis with rapamycin].
Med Klin (Munich) 2005, 100(3):161–164.
5. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA,
Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate
epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
Nat Cell Biol 2008, 10(5):593–601.
6. Cho JH, Gelinas R, Wang K, Etheridge A, Piper MG, Batte K, Dakhallah D,
Price J, Bornman D, Zhang S, March C, Galas D: Systems biology of
interstitial lung diseases: integration of mRNA and microRNA expression
changes. BMC Med Genomics 2011, 4:8.
7. Shimizu Y, Dobashi K, Iizuka K, Horie T, Suzuki K, Tukagoshi H, Nakazawa T,
Nakazato Y, Mori M: Contribution of small GTPase Rho and its target
protein rock in a murine model of lung fibrosis. Am J Respir Crit Care Med
2001, 163(1):210–217.
8. American Thoracic Society/European Respiratory Society : American
Thoracic Society/European respiratory society international
multidisciplinary consensus classification of the idiopathic interstitial
pneumonias. Am J Respir Crit Care Med 2002, 165(2):277–304.
9. Park YS, Park CM, Lee HJ, Goo JM, Chung DH, Lee SM, Yim JJ, Kim YW, Han SK,
Yoo CG: Clinical implication of protease-activated receptor-2 in idiopathic
pulmonary fibrosis. Respir Med 2013, 107(2):256–262.
10. Ashcroft T, Simpson JM, Timbrell V: Simple method of estimating severity
of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988, 41(4):467–470.
11. Akira M, Sakatani M, Ueda E: Idiopathic pulmonary fibrosis: progression of
honeycombing at thin-section CT. Radiology 1993, 189(3):687–691.
12. Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway.
Curr Opin Cell Biol 2005, 17(6):596–603.
13. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G,
Rama I, Vidal A, Grinyo JM:Mammalian target of rapamycin pathway blockade
slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006,
17(5):1395–1404.
14. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ: Rapamycin
attenuates unilateral ureteral obstruction-induced renal fibrosis.
Kidney Int 2006, 69(11):2029–2036.
15. Kramer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H,
Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H: Low-dose
mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced
chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 2008,
294(2):F440–449.
Park et al. BMC Pulmonary Medicine 2014, 14:168 Page 9 of 9
http://www.biomedcentral.com/1471-2466/14/16816. Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C,
Stickel F: Potent antifibrotic activity of mTOR inhibitors sirolimus and
everolimus but not of cyclosporine A and tacrolimus in experimental
liver fibrosis. J Hepatol 2011, 55(2):388–398.
17. Mehrad B, Burdick MD, Strieter RM: Fibrocyte CXCR4 regulation as a
therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009,
41(8–9):1708–1718.
18. Simler NR, Howell DC, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ,
Chambers RC, Egan JJ: The rapamycin analogue SDZ RAD attenuates
bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 2002,
19(6):1124–1127.
19. Fernandez IE, Eickelberg O: New cellular and molecular mechanisms of
lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012,
380(9842):680–688.
20. Nair RV, Huang X, Shorthouse R, Adams B, Brazelton T, Braun-Dullaeus R,
Morris RE: Antiproliferative effect of rapamycin on growth factor-stimulated
human adult lung fibroblasts in vitro may explain its superior efficacy for
prevention and treatment of allograft obliterative airway disease in vivo.
Transplant Proc 1997, 29(1–2):614–615.
21. Gao Y, Xu X, Ding K, Liang Y, Jiang D, Dai H: Rapamycin inhibits transforming
growth factor beta1-induced fibrogenesis in primary human lung fibroblasts.
Yonsei Med J 2013, 54(2):437–444.
22. Clinicaltrials.gov, A service of the U.S. National Institutes of Health. http://
clinicaltrials.gov/ct2/show/NCT01462006?term=mTOR%2C+idiopathic
+pulmonary+fibrosis&rank=1.
23. ten Dijke P, Hill CS: New insights into TGF-beta-Smad signalling.
Trends Biochem Sci 2004, 29(5):265–273.
24. Aigner K, Descovich L, Mikula M, Sultan A, Dampier B, Bonne S, van Roy F,
Mikulits W, Schreiber M, Brabletz T, Sommergruber W, Schweifer N,
Wernitznig A, Beug H, Foisner R, Eger A: The transcription factor ZEB1
(deltaEF1) represses Plakophilin 3 during human cancer progression.
FEBS Lett 2007, 581(8):1617–1624.
25. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME,
Arteaga CL, Moses HL: Transforming growth factor-beta1 mediates
epithelial to mesenchymal transdifferentiation through a RhoA-
dependent mechanism. Mol Biol Cell 2001, 12(1):27–36.
26. Das S, Becker BN, Hoffmann FM, Mertz JE: Complete reversal of epithelial
to mesenchymal transition requires inhibition of both ZEB expression
and the Rho pathway. BMC Cell Biol 2009, 10:94.
doi:10.1186/1471-2466-14-168
Cite this article as: Park et al.: Clinical significance of mTOR, ZEB1,
ROCK1 expression in lung tissues of pulmonary fibrosis patients. BMC
Pulmonary Medicine 2014 14:168.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
